Runners and riders in the Covid vaccine race

Pfizer, AstraZeneca and Moderna have won approval for their Covid vaccines from the United kingdom regulator and the jabs are already staying rolled out. But what about the other vaccine candidates and how soon will they come to market place?

Our record gives a snapshot of what the vaccine landscape appears to be like like.

The life sciences industry’s response to the pandemic has been unparalleled equally in conditions of the speed at which it has produced vaccines and its willingness to collaborate with rivals. That has resulted in 237 potential vaccines, of which 64 are in human clinical trials.

That’s good news as, in the vaccines business there is normally no “1-measurement-fits-all” solution, with different nations requiring different types of vaccines primarily based on a array of variables which includes local weather, land mass and demography. In other terms: there is a great deal of space in the market place for additional than 1 vaccine.

Covid vaccines accredited by the United kingdom

Pfizer/BioNtech

United kingdom approval date: December 2, 2020

Doses: 2

Efficacy: 90pc +

Form: mRNA

Doses sold or pre-ordered globally: The full sum is undisclosed, but we know it has 300m on purchase from the EU and 200m from the US, which, alongside one another with the United kingdom, delivers the full to 540m

Doses procured by the United kingdom: 40m

Manufacturing ability: Up to 2bn doses this 12 months